In February 2026, Nektar announced a $300 million underwritten public offering of common stock and pre-funded warrants, with proceeds intended for research and development, clinical development including Phase 3 trials for rezpegaldesleukin, and manufacturing costs. The company announced in February 2026 an academic research collaboration with UCSF for NKTR-0165, a novel, first-in-class tumor necrosis factor receptor 2 (TNFR2) agonist antibody.
Cyborg Score Rationale
Nektar has advanced its lead candidate into Phase 2b/3 territories with reasonable cash runway and a focused immunology portfolio. However, the company faces significant execution risk, competitive pressure from established players like Dupilumab in atopic dermatitis, and clinical proof-of-concept challenges. The biotech funding environment remains supportive, but pipeline advancement depends heavily on Phase 2b/3 data readouts.
Top Insights
Phase 3 ZENITH-AD program for rezpegaldesleukin in atopic dermatitis is expected to initiate by July 2026
UCSF research collaboration announced in February 2026 to explore NKTR-0165 in multiple sclerosis, expanding clinical applicability
Diversified pipeline includes TNFR2-based programs (NKTR-0165, NKTR-0166), CSF program (NKTR-422), and IL-15 agonist (NKTR-255) for oncology partnerships
Recent $300 million capital raise in February 2026 provides significant runway to advance clinical programs and manufacturing scale-up
Named Competitors
Dupixent — Leading biologic for atopic dermatitis
Imfinzi — PD-L1 checkpoint inhibitor
Bavencio — PD-L1 checkpoint inhibitor
Recent Developments
(February 2026) $300 million public offering announced to fund Phase 3 trials and manufacturing for rezpegaldesleukin
(February 2026) Research collaboration with UCSF and Dr. Stephen Hauser announced for NKTR-0165 in multiple sclerosis
(June 2026) Phase 3 ZENITH-AD program for rezpegaldesleukin in atopic dermatitis expected to initiate by July 2026
Open the full interactive Nektar Therapeutics report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.